Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1776, Issue 1, Pages 58-85Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2007.06.003
Keywords
RASSF; tumour suppressor; methylation; cell cycle; apoptosis; microtubule
Categories
Funding
- Cancer Research UK [A6997] Funding Source: Medline
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
Ras proteins play a direct causal role in human cancer with activating mutations in Ras occurring in similar to 30% of tumours. Ras effectors also to cancer, as mutations occur in Ras effectors, notably B-Raf and P13-K, and drugs blocking elements of these pathways are in clinical development. In 2000, a new Ras effector was identified, RAS-association domain family 1 (RASSF1), and expression of the RASSF1A isoform of this gene is silenced in tumours by methylation of its promoter. Since methylation is reversible and demethylating agents are currently being used in clinical trials, detection of RASSF1A silencing by promoter hypermethylation has potential clinical uses in cancer diagnosis, prognosis and treatment. RASSF1A belongs to a new family of RAS effectors, of which there are currently 8 members (RASSF1-8). RASSF1-6 each contain a variable N-terminal segment followed by a Ras-association (RA) domain of the Ral-GDS/AF6 type, and a specialised coiled-coil structure known as a SARAH domain extending to the C-terminus. RASSF7-8 contain an N-terminal RA domain and a variable C-terminus. Members of the RASSF family are thought to function as tumour suppressors by regulating the cell cycle and apoptosis. This review will summarise our current knowledge of each member of the RASSF family and in particular what role they play in tumourigenesis, with a special focus on RASSF1A, whose promoter methylation is one of the most frequent alterations found in human tumours. (c) 2007 Elsevier B.V All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available